- Home
- DCI vs ABVX Comparison
DCI vs ABVX Comparison
Compare DCI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCI | ABVX |
|---|---|---|
| Founded | 1915 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.9B |
| IPO Year | 2005 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DCI | ABVX |
|---|---|---|
| Price | $90.60 | $114.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $99.00 | ★ $131.31 |
| AVG Volume (30 Days) | 590.8K | ★ 800.9K |
| Earning Date | 06-02-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | N/A |
| Revenue This Year | $4.58 | $52.14 |
| Revenue Next Year | $5.18 | $4,132.27 |
| P/E Ratio | $32.69 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $79.47 | $69.81 |
| 52 Week High | $112.84 | $148.83 |
Technical Indicators
Market Signals| Indicator | DCI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 43.20 |
| Support Level | $85.72 | $107.67 |
| Resistance Level | $91.99 | $129.00 |
| Average True Range (ATR) | 2.27 | 3.63 |
| MACD | -0.65 | -0.48 |
| Stochastic Oscillator | 16.55 | 33.75 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.